Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy

被引:0
|
作者
Waede, Mie [1 ,2 ,3 ]
Voss, Lasse F. [4 ]
Kingo, Christina [1 ,2 ,3 ]
Moeller, Jesper B. [3 ,5 ]
Elkjaer, Maria L. [1 ,2 ,3 ,6 ]
Illes, Zsolt [1 ,2 ,3 ,7 ]
机构
[1] Odense Univ Hosp, Dept Neurol, Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[3] Univ Southern Denmark, Dept Mol Med, Odense, Denmark
[4] Tech Univ Denmark, Dept Hlth Technol, Sect Expt & Translat Immunol, Lyngby, Denmark
[5] Univ Southern Denmark, Danish Inst Adv Study, Odense, Denmark
[6] Univ Hamburg, Inst Computat Syst Biol, Hamburg, Germany
[7] Univ Southern Denmark, BRIDGE Brain Res Interdisciplinary Guided Excellen, Odense, Denmark
来源
关键词
NATURAL-KILLER-CELLS; T-CELLS; CHEMOKINE RECEPTORS; NK CELLS; CEREBROSPINAL-FLUID; ACTIVATION; EXPRESSION; RITUXIMAB; CD38; INFLAMMATION;
D O I
10.1002/acn3.52182
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Anti-CD20 therapy is a highly effective treatment for multiple scle-rosis (MS). In this study, we investigated MS-related changes in peripheralblood mononuclear cell (PBMC) subsets compared to healthy controls and lon-gitudinal changes related to the treatment.Methods: Multicolor spectral flowcytometry analysis was performed on 78 samples to characterize disease- andtreatment-related PBMC clusters. Blood samples from MS patients were col-lected at baseline and up to 8 months post-treatment, with three collectionpoints after treatment initiation. Unsupervised clustering tools and manual gat-ing were applied to identify subclusters of interest and quantify changes. Results: B cells were depleted from the periphery after anti-CD20 treatment asexpected, and we observed an isolated acute, transitory drop in the proportionof natural killer (NK) and NKT cells among the main populations of PBMC(P=0.03,P=0.004). Major affected PBMC subpopulations were cytotoxicimmune cells (NK, NKT, and CD8(+)T cells), and we observed a higher propor-tion of cytotoxic cells with reduced brain-homing ability and a higher regula-tory function as a long-term anti-CD20-related effect. Additionally, anti-CD20therapy altered distributions of memory CD8(+)T cells and reduced exhaustionmarkers in both CD4(+)and CD8(+)T cells.Interpretation: The findings of thisstudy elucidate phenotypic clusters of NK and CD8(+)T cells, which have previ-ously been underexplored in the context of anti-CD20 therapy. Phenotypicmodifications towards a more regulatory and controlled phenotype suggest thatthese subpopulations may play a critical and previously unrecognized role inmediating the therapeutic efficacy of anti-CD20 treatments.
引用
收藏
页码:2657 / 2672
页数:16
相关论文
共 50 条
  • [41] Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
    Roach, Charles A.
    Cross, Anne H.
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [42] Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
    Florou, Despoina
    Katsara, Maria
    Feehan, Jack
    Dardiotis, Efthimios
    Apostolopoulos, Vasso
    BRAIN SCIENCES, 2020, 10 (10) : 1 - 13
  • [43] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
    Finn Sellebjerg
    Morten Blinkenberg
    Per Soelberg Sorensen
    CNS Drugs, 2020, 34 : 269 - 280
  • [44] Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies
    Nicolas, Philippe
    Marion-Moffet, Hugo
    Gossez, Morgane
    Vukusic, Sandra
    Monneret, Guillaume
    Marignier, Romain
    Venet, Fabienne
    JOURNAL OF NEUROLOGY, 2023, 270 (01) : 32 - 36
  • [45] Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies
    Philippe Nicolas
    Hugo Marion-Moffet
    Morgane Gossez
    Sandra Vukusic
    Guillaume Monneret
    Romain Marignier
    Fabienne Venet
    Journal of Neurology, 2023, 270 : 32 - 36
  • [46] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
    Sellebjerg, Finn
    Blinkenberg, Morten
    Sorensen, Per Soelberg
    CNS DRUGS, 2020, 34 (03) : 269 - 280
  • [47] Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
    de Seze, Jerome
    Maillart, Elisabeth
    Gueguen, Antoine
    Laplaud, David A. A.
    Michel, Laure
    Thouvenot, Eric
    Zephir, Helene
    Zimmer, Luc
    Biotti, Damien
    Liblau, Roland
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [48] Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis
    Howlett-Prieto, Quentin
    Feng, Xuan
    Kramer, John F.
    Kramer, Kevin J.
    Houston, Timothy W.
    Reder, Anthony T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (14) : 2170 - 2179
  • [49] Anti-CD20 monoclonal antibody therapy in multiple myeloma
    Kapoor, Prashant
    Greipp, Patricia T.
    Morice, William G.
    Rajkumar, S. Vincent
    Witzig, Thomas E.
    Greipp, Philip R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (02) : 135 - 148
  • [50] Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis
    Cotchett, Kelly R.
    Dittel, Bonnie N.
    Obeidat, Ahmed Z.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 49